iBio Inc. (NASDAQ: IBIO) announced it has dosed the first participant in a Phase 1 clinical trial of IBIO-600, an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE